SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing significant downward pressure driven by market apprehension surrounding Donald Trump's extended and often incoherent public address, where his discussion of tariffs and Greenland policy raises concerns about global trade stability. Community sentiment is deeply divided, with many expressing alarm over potential economic repercussions while a subset anticipates a swift "buy the dip" recovery from the current volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst a persistent downtrend, causing frustration among some investors profiting from puts, while others aggressively "buy the dip" citing historically oversold conditions. This comes ahead of its anticipated strong December-quarter earnings, with bulls expecting robust iPhone demand and new AI partnerships with Google Gemini, despite ongoing concerns about memory chip costs and broader geopolitical trade tensions.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in attention following a pivotal FDA meeting for its ANKTIVA bladder cancer treatment, where regulators reportedly indicated no requirement for new clinical trials and requested additional data for submission within 30 days. This news has ignited strong community discussion, with investors buzzing about a potential short squeeze and highlighting ANKTIVA's broad therapeutic promise across various cancer indications. The stock's robust performance amid a challenging market is drawing significant interest, as many anticipate further positive developments and substantial long-term growth for this biotech company.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant technology, widely seen by the community as a validation of its core platform. This development has fueled expectations of further partnerships and a potential short squeeze, with many closely watching how management addresses continued activist investor pressure for enhanced shareholder value.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

ProShares Ultra VIX Short-Term Futures ETF ($UVXY) is actively trending as traders weigh potential market volatility driven by discussions surrounding recent geopolitical developments, including international tariffs, and the anticipated Bank of Japan rate hike. The community is sharply divided, with many actively debating short positions on $UVXY due to its inherent decay, while others anticipate a volatility spike, expressing frustration over its subdued movement despite broader market fluctuations.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is a prominent trending topic, experiencing pre-market declines amid broader market volatility and geopolitical trade tensions. The community is actively debating a potential "red to green" recovery, with bulls "buying the dip" while bears highlight growing competition from international EV brands and express skepticism about the company's ambitious AI and robotics initiatives. This discussion occurs as the market anticipates upcoming earnings and recent news regarding the company's accelerated AI chip development.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8%

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling...

<ul class="summary-bullets"><li>FDA is slated to decide on Disc Medicine's Bitopertin by February.&nbsp;</li><li>Approval for Lilly’s obesity pill is expected by April 10.</li><li>The FDA has also stalled the review of Sanofi’s Tzield for late-stage type 1 diabetes by more than a month over adverse event reports, Reuters said.</li></ul>Shares of Disc Medicine (IRON) fell 7% on Thursday after the U.S. Food and Drug Administration (FDA) reportedly delayed review of its drug Bitopertin despite choosing it for fast track review under a new voucher program.Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/us-fda-delays-two-drug-reviews-new-voucher-program-after-safety-efficacy-2026-01-15/">reported</a> on Thursday, citing internal documents, that the FDA delayed the review of the company’s experimental drug for treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns. EPP is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight and artificial light, leading to immediate, painful skin reactions like burning, redness, and swelling.The reviewers pushed the drug’s potential approval by two weeks to Feb. 10 as they examine whether it has abuse risks. The agency also has concerns if pain-free time in the sun is a statistically solid measure of efficacy or if other data can justify approval, the report said.Disc Medicine’s Bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program announced in June 2025. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.<h2 class="st-heading-2">Sanofi Faces Longer Delay</h2>The FDA has also stalled the review of Sanofi’s (SNY) Tzield for late-stage type 1 diabetes by more than a month over adverse event reports, Reuters said.The agency is considering the death of a patient while taking the drug and also evaluating two reports related to seizure and blood clotting. The agency was initially slated to decide on the application by Nov. 21.<h2 class="st-heading-2">Lilly’s Weight-Loss Drug Approval Now Slated For Q2</h2>Other drugs to face delays beyond the original target date include Boehringer Ingelheim's zongertinib for lung cancer and Eli Lilly’s (LLY) weight-loss pill. While zongertinib approval is now expected in mid-February, approval for Lilly’s obesity pill is expected by April 10, later than its initial first quarter (Q1) estimate, Reuters said.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> traded 4% lower at the time of writing while <a href="https://stocktwits.com/symbol/SNY">SNY shares</a> fell 1%.According to Reuters, at least seven drugs selected for priority review have started the approval process. While most of the reviews for the drugs selected for the program are slated to start this year, others are scheduled for 2027 and 2028.Only one antibiotic drug has been approved under the program as of date called Augmentin XR.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON and SNY stocks trended in the ‘Neutral’ territory at the time of writing. Retail sentiment around LLY, however, rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours.A Stocktwits user dismissed the delay report as a “short term hiccup.”<stembedurl>https://www.stocktwits.com/wwmeinc/message/641906137</stembedurl>Another opined that the selloff in IRON shares is a buying opportunity.<stembedurl>https://www.stocktwits.com/StockBraker/message/641896960</stembedurl><a href="https://stocktwits.com/symbol/IRON">IRON stock</a> has gained 18% over the past 12 months. &nbsp;&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-contemplating-deal-with-chinese-rival-byd-as-it-seeks-to-scale-hybrids-report/cmU1pwgR4JJ">Ford Contemplating Deal With Chinese Rival BYD As It Seeks To Scale Hybrids: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers

Reuters reported on Thursday that the FDA delayed the review of Disc Medicine’s experimental drug for the treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns.

Equity

Reuters reported on Thursday that the FDA delayed the review of Disc Medicine’s experimental drug for the treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns.


Disc Medicine (NASDAQ:IRON) Shares Gap Down - Should You Sell?

Disc Medicine (NASDAQ:IRON) Shares Gap Down - What's Next...

Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 6,500 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 6,500 shares of Disc Medicine stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an...

Disc Medicine (NASDAQ:IRON) Insider Sells $511,485.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 6,500 shares of the company's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price...

Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirteen brokerages that are presently covering the company, Marketbeat...

<ul class="summary-bullets"><li>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule.&nbsp;</li><li>Wall Street analysts dismissed the media report hinting at approval delays and termed the share drop as overblown.&nbsp;</li><li>Disc Medicine is hopeful for an approval of the drug by the end of January 2026.</li></ul>Shares of Disc Medicine (<a href="https://stocktwits.com/symbol/IRON">IRON</a>) plunged 12% on Friday after a report flagged concerns pertaining to the U.S. Food and Drug Administration’s speedy approval of the company’s blood disorder drug Bitopertin.Disk Medicine’s Biopertin for the treatment of Erythropoietic Protoporphyria (EPP) is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program. The Commissioner's National Priority Voucher program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.However, Stat News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/12/19/fda-voucher-program-political-interference/">reported</a> on Friday, citing government officials, that high-level FDA officials have been involved in every part of the new program involving the vouchers. The political pressure is creating “uncomfortable situations” for career scientists at the FDA, the report said.The report dragged down investor sentiment and hopes for an expedited approval of Bitopertin as the report also noted that FDA senior official Vinay Prasad raised doubts about the drug’s effectiveness.<h2 class="st-heading-2">Wall Street Dismisses Concerns</h2>Jefferies analyst Roger Song, however, termed the share drop a “stock overreaction”. Song said that while the priority voucher program's timeline may be under pressure with increasing demand, the firm remains confident on Bitopertin's approval in EPP under the program, based on robust efficacy and safety data and to-date review experience.TD Cowen also maintained its ‘Buy’ rating on the shares and said the firm believes skepticism on the program’s path is overblown. Disc's management remains confident, it noted, and added that the firm's confidence in accelerated approval remains high.BMO Capital said that it had discussions with Disc Medicine’s management which highlighted a lack of interactions with senior official Prasad but robust active dialogue with the FDA. While Prasad may have speculated efficacy concerns related to Bitopertin, these have not been communicated to Disc, and no clear concerning questions around efficacy have been raised, BMO added. Some procedural questions have been asked by FDA in trying to understand the Bitopertin data package and how it may translate to clinical benefit, it said. The firm has an ‘Outperform’ rating on the shares with a price target of $120.<h2 class="st-heading-2">Management Takeaway</h2>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule and expressed hopes for potential launch by the end of January 2026, consistent with the 1-2 month timeline for drugs which receive the priority voucher.“Our commercialization efforts have been accelerated significantly and we are well on our way to launch readiness,” the company said.The company submitted its application for approval in patients aged 12 years and older with EPP on September 29. Erythropoietic Protoporphyria (EPP) is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight (phototoxicity), leading to immediate, painful skin reactions like burning, tingling, redness, and swelling, due to the buildup of protoporphyrin in red blood cells from an enzyme deficiency.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON stayed within the ‘bearish’ territory while message volume rose from ‘low’ to ‘high’ levels.IRON stock has gained about 26% this year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-intel-shares-jump-after-us-antitrust-agencies-clear-5-billion-deal/cLe0d1gREtc">Nvidia, Intel Shares Jump After US Antitrust Agencies Clear $5B Deal That Deepens Their Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’

Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program. 

Disc Medicine Enters Oversold Territory (IRON)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Disc Medicine (NASDAQ:IRON) Shares Down 9% After Insider Selling

Disc Medicine (NASDAQ:IRON) Shares Down 9% Following Insider Selling...

Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 754 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Kevin Bitterman sold 754 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold...

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

IRON
Disc Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IRON News

IRONDisc Medicine Inc